Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
October 22 2018 - 8:30AM
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX)
announced today its participation at premier conferences including
the American Society of Nephrology (ASN) Kidney Week 2018, Clinical
Trials on Alzheimer’s Disease (CTAD) 2018 and the American Heart
Association (AHA) Scientific Sessions 2018. Through participation
at major conferences and events, the company continues to highlight
apabetalone (the first BET inhibitor in a Phase 3 clinical trial
for high-risk vascular disease, BETonMACE) and its ability to
regulate multiple biological pathways that underlie disease and are
known to contribute to cardiovascular, diabetes and
neurodegenerative diseases.
The BETonMACE trial is expected to be complete
around the end of 2018 with the topline results expected shortly
thereafter.
ASN Kidney Week 2018, San Diego, CA
|
• |
October 26, 2018 from
10:00 AM to 12:00 PM |
|
|
- Session Title: Molecular Mechanisms of CKD - II
- Poster: Apabetalone Downregulates Factors and Pathways
Associated with Vascular Calcification
|
CTAD 2018, Barcelona, Spain
|
• |
October 25 – October 27,
2018 |
|
|
- Poster: Apabetalone, a BET Bromodomain Inhibitor,
Suppresses Inflammatory Mediators in Microglia and Vascular
Endothelial Cells that Contribute to Neurodegenerative Disease
|
AHA Scientific Sessions 2018, Chicago, IL
|
• |
November 11, 2018 from
10:30 AM to 11:45 AM |
|
|
- Session: Cardiovascular Disease Prevention
- Poster: Cardiovascular Evaluation of the Selective Bet
Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline
Characteristics of the BETonMACE CV Outcomes Study
|
|
• |
November
12, 2018 – 1:00 PM – 2:15 PM |
|
|
- Session: The Immune System Aggravating Cardiovascular
Diseases
- Poster: Apabetalone (RVX-208) Suppresses Expression of Key
Vascular Inflammation Markers in Monocytes, Endothelial Cells and
LPS-Challenged Mouse Liver and Monocyte Adhesiveness to Activated
Endothelial Cells
|
Posters will be available on the Company’s website here at the
appropriate time.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease, diabetes mellitus,
chronic kidney disease, end-stage renal disease treated with
hemodialysis, neurodegenerative disease, Fabry disease, peripheral
artery disease and other orphan diseases, while maintaining a well
described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
This news release may contain certain
forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward
looking information relating to the timing of the BETonMACE trial
and the potential role of apabetalone in the treatment of high-risk
vascular diseases including CVD, DM and neurodegenerative diseases.
Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including those discussed in our Annual Information
Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR at www.sedar.com. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024